The case to research the addition of Poly-ICLC and Flt3L molecules to increase efficacy of low efficacy covid-19 vaccines

Very recently a new melanoma vaccine reached phase 3 testing in human subjects. This new vaccine uses two components, Poly-ICLC and Flt3L Molecules [1] — colorfully referred by its researchers as boosters — that according with the main scientist could perhaps be used in the future in other types of vaccines to significantly increase its effectiveness. [2]

Pertaining to the novel covid-19 virus, one could experiment adding these boosters to the BCG vaccine which seems to have some sort of protective effect against covid-19. [3] Given its high safety — it’s been in existence for several decades — and the required industrial processes already exist for mass production it seems medically relevant to scientifically research this possibility.

There is a myriad of covid-19 vaccines in development struggling with low efficacy that could, perhaps, benefit from the addition of such boosters. Why not try this in a scientific setting? Those components were approved in the aforementioned melanoma vaccine clinical trial and have successfully concluded phase 2 — which may indicate its safety to a sufficient degree as to initiate a clinical trial with these boosters on existing covid-19 low efficacy vaccines in a scientific research.

Considering the current need for effective vaccines against this disease, this research could perhaps be helpful to the current effort.

[1] https://www.nature.com/articles/s43018-020-00143-y
[2] https://www.mountsinai.org/about/newsroom/2020/mount-sinai-researchers-discover-how-to-boost-efficacy-of-vaccine-designed-to-prevent-melanoma-recurrence-pr
[3] https://www.nature.com/articles/s41598-020-80787-z